Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Gliosarcoma 1

Interventions

Paclitaxel 9Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Cisplatin 8Carboplatin 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Radiotherapy, Intensity-Modulated 6Nivolumab 6Leucovorin 6Filgrastim 6Drug Therapy 6Doxorubicin 6Radiotherapy 5Oxaliplatin 5Fluorouracil 5Docetaxel 5Bevacizumab 5pembrolizumab 4gallium 68 PSMA-11 4Taxes 4Sirolimus 4Rituximab 4Pemetrexed 4Melphalan 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Contrast Media × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡